Compare
Boundless Bio, Inc. vs Precigen, Inc. vs Xilio Therapeutics, Inc. vs Aclaris Therapeutics, Inc.
| Latest fiscal year | Boundless Bio, Inc. BOLD | Precigen, Inc. PGEN | Xilio Therapeutics, Inc. XLO | Aclaris Therapeutics, Inc. ACRS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $9.68M | $43.77M | $7.83M |
| Revenue growth (YoY) | n/a | +146.7% | +589.9% | -58.2% |
| Gross margin | n/a | n/a | n/a | 73.3% (computed) |
| Operating margin | n/a | n/m | -95.9% | -975.9% |
| Net margin | n/a | n/m | -80.1% | -829.6% |
| Net income | -$58.20M | -$250.64M | -$35.04M | -$64.92M |
| EPS (Diluted) | -$2.60 | -$1.37 | -$4.19 | -$0.53 |
| Operating cash flow | -$46.66M | -$87.83M | -$4.99M | -$47.11M |
| Free cash flow | -$47.21M | -$89.83M | -$5.51M | -$47.22M |
| Cash & equivalents | $17.87M | $30.23M | $137.53M | $19.96M |
| Total assets | $157.06M | $155.50M | $154.69M | $160.46M |
| Total liabilities | $58.41M | $134.59M | $119.41M | $57.38M |
| Shareholders' equity | $98.65M | $20.91M | $35.27M | $103.08M |
| Return on year-end equity | -59.0% | n/m | -99.3% | -63.0% |
| Shares outstanding | 22.41M | 353.91M | 4.53M | 120.50M |
Revenue, most recent five fiscal years
| Fiscal year | Boundless Bio, Inc. | Precigen, Inc. | Xilio Therapeutics, Inc. | Aclaris Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $9.68M Ended 2025-12-31 | $43.77M Ended 2025-12-31 | $7.83M Ended 2025-12-31 |
| 1 year earlier | n/a | $3.92M Ended 2024-12-31 | $6.34M Ended 2024-12-31 | $18.72M Ended 2024-12-31 |
| 2 years earlier | n/a | $6.22M Ended 2023-12-31 | n/a | $31.25M Ended 2023-12-31 |
| 3 years earlier | n/a | $26.91M Ended 2022-12-31 | n/a | $29.75M Ended 2022-12-31 |
| 4 years earlier | n/a | $14.27M Ended 2021-12-31 | n/a | $6.76M Ended 2021-12-31 |